The success of the science-medicine synergism and dramatic acceleration in enabling technologies results today, more than even, in translation of scientific “dream” into medical reality. What have motivated me previously as a science student, and is inspiring me today is the translation of our scientific discoveries into improvement in health and quality of life.
As a researcher, who worked on CFTR gene regulation and stability, I am especially excited about the first treatment, available on the market, to target the underlying cause of Cystic Fibrosis. Although KALYDECO (Vertex) is targeted to improve CFTR function in patients with G551D mutation, there are multiple targeted approaches to cystic fibrosis treatment for people with different CFTR mutations.
If you want to know more about this new medicine, please visit Vertex website.